Newgen Software share price rallies over 4% after Jefferies raises target

Newgen Software Technologies share price rallied over 4% on Monday after foreign brokerage firm Jefferies raised target price on the stock. Newgen Software shares gained as much as 4.16% to 1,474.00 apiece on the BSE.

Jefferies maintained a ‘Buy’ rating on Newgen Software Technologies and raised the target price to 1,740 per share, based on 35x PE, implying a PEG of 1.3x, from earlier 1,275.

The brokerage said it was more confident on Newgen’s growth outlook and raised its revenue estimates by 2-3% and EPS estimates by 2-4%.

“We expect Newgen to deliver a strong 26% EPS Cagr over FY24-26E,” Jefferies said.

Also Read: BSE share price has more 25% upside potential, says Sharekhan; here’s why

At its Annual event, Newgen Software’s management highlighted that growth outlook remains strong and recent bookings offer comfort on FY24 growth. The strong growth outlook is driven primarily by India and the Middle East – its core markets – while it continues to scale up in APAC. Management continues to step up efforts to gain traction in the US, especially among the mid-large tier banks.

India is witnessing strong traction and deal sizes have increased by 40% over the last year. Its trade finance product has had 9 large deal wins and provides strong growth visibility in the future.

(Exciting news! Mint is now on WhatsApp Channels :rocket: Subscribe today by clicking the link and stay updated with the latest financial insights! Click here!)

The company’s management highlighted that Newgen’s gross margins could expand by 10-12 ppts once they reach a topline of $350 million. However, management plans to re-invest most of the potential margin improvement either to scale up its marketing efforts or to invest in product development in order to accelerate growth.

“This should limit Ebitda margin expansion in the future. We thus expect our FY24-26 margins to remain around the 22% range,” Jefferies said.

Also Read: BCL Industries shares hit life-time high on ethanol supply orders from OMCs

In its base case scenario, the brokerage expects the company to deliver revenue growth of 24% Cagr and EBITDA margin of 22% over FY24-26E.

The key catalyst for the stock would be traction in deal wins, including in the US, leading to higher-than-expected revenue growth, beat in margins, lower receivable/debtor days and favorable currency movement, according to Jefferies.

At 2:40 pm, Newgen Software Technologies shares were trading 1.20% higher at 1,432.00 apiece on the BSE.

Catch Live Market Updates here

Disclaimer: The views and recommendations made above are those of individual analysts or brokering companies, and not of Mint. We advise investors to check with certified experts before taking any investment decisions.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it’s all here, just a click away! Login Now!

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.

More Less

Published: 04 Dec 2023, 02:42 PM IST

Turquoise Health Raises $30M for its Price Transparency Software

price transparency

Hospitals’ compliance with price transparency laws has increased In the past year, with most hospitals currently displaying the cost data they need to in order to comply significantly with the regulations. That wasn’t always the case, though. Hospitals had a difficult time meeting CMS’ price transparency requirements during the first two years they were enforced — a JAMA study published a year and a half after the rule went into effect showed that fewer than 6% of US hospitals were fully compliant.

To achieve compliance, many health systems have turned to technology vendors for assistance. One of these vendors — Turquoise Healtha San Diego-based startup selling software to reduce the complexity of healthcare pricing data — announced a new funding round on Tuesday.

The startup, which was founded in 2020, completed a $30 million Series B round, which brings its total funding to date to $55 million. The financing round was led by Adams Street Partnerswith participation from Andreessen Horowitz, BoxGroup and Yosemite. Adams Street Partner Tom Bremner will join Turquoise’s board of directors.

“Healthcare pricing remains frustratingly opaque for many industry stakeholders, including pattention,” Bremner said in a statement. “Turquoise tackles this problem head-on with a sophisticated, multi-stakeholder platform that ultimately makes healthcare pricing and packaging look easy. I am excited to partner with the team as they scale towards a seamless healthcare transaction.”

CMS began enforcing it price transparency rules on the first day of 2021. The law requires hospitals to post their gross charges, payer-specific negotiated charges, de-identified minimum negotiated charges, de-identified maximum negotiated charges and cash prices on their websites in a machine-readable file. It also mandates that hospitals must publish pricing for the 300 most commonly used services to their website in a consumer-friendly manner.

In July 2022, CMS began requiring payers to post price transparency data as well. Payers are required to post rate data for more than the services they cover at hospitals — they must publish data for all types of providers, such as imaging centers, family practice clinics, and ambulatory surgery centers.

Both hospitals and payers are required to post massive amounts of data in a consumer-friendly manner, which isn’t an easy task given the highly complex and variable nature of healthcare financial data, Turquoise CEO Chris Severn pointed out.

The complicated structure of the healthcare system — from care variance to deductibles to billing codes — means that producing an accurate price estimate is incredibly challenging. For example, there is no single price for a colonoscopy or hysterectomy. In order to figure out how much a procedure will actually cost a patient, a number of variables need to be considered, such as the facility fee, doctor’s procedure fee and anesthesia fee.

That’s why Turquoise built software to quickly gather that information and determine what a patient’s health plan will pay for. The startup’s platform provides direct access to price transparency data via a search engine, as well as tools for data viewing and reporting. Overall, this platform makes it easier to quickly provide patients with an accurate price quote, Severn explained.

Turquoise has more than 160 customers, including providers, payers, employers, consultants, health tech companies, pharmaceutical firms and medical device makers. These customers contribute to the startup’s revenue via three streams, which Severn categorized as “data, contracts and compliance.”

The data revenue stream refers to customers who buy access to negotiated rates and cash prices from providers and payers across the country. The contracts stream encompasses those that use Turquoise’s contract intelligence platform, which leverages AI to enable contract organization and insights. As for the compliance stream, this involves customers that use Turquoise’s compliance tools designed for CMS’ price transparency laws and the No Surprises Act.

There are other companies out there that also help healthcare organizations understand costs and negotiate accordingly, like Accenture, Deloitte and Healthcare Bluebook. Severn declined to answer MedCity News‘ question asking how Turquoise differentiates itself from competitors such as these.

Photo: cinemaslow, Getty Images

IBM expands its software portfolio to India and 92 other nations in AWS Marketplace | Technology News

Tech giant IBM has announced that it is expanding its software portfolio globally to 92 countries in AWS Marketplace. For the uninitiated, AWS Marketplace is a digital catalog that features thousands of software listings from independent software vendors or (ISVs) making it easier to search, test, purchase, and deploy software that runs on Amazon Web Services (AWS).

This expansion beyond Denmark, Germany, France, the UK, and the US will make it easy for clients to streamline purchasing and create new efficiencies. Based on a recent study by Canalys, cloud marketplaces like AWS continue to emerge as the fastest-growing route to market for Software-as-a-Service (SaaS) software. This is expected to increase to $45 billion by 2025, up 84 per cent CAGR over five years. It needs to be noted that marketplaces also help shorten the buying cycle, consolidate billing, and make it easier to scale software deployments instantly.

With the latest development, companies will now have access to IBM’s AI and data technologies within a portfolio of 44 listings and 29 SaaS offerings available for purchase. The listed technologies include WatsonX AI and a data platform that allows companies to build, scale, and manage AI workloads. Watsonx.data, a fit-for-purpose data store built on an open data lakehouse architecture, and Watsonx.ai, a next-generation enterprise studio for AI builders are available in the AWS Marketplace as well as two of IBM’s AI Assistants — watsonx Assistant and watsonx Orchestrate. Watsonx. governance is expected to be available soon.

Other software includes IBM’s flagship database Db2 Cloud Pak for Data and a portfolio of automation software including Apptio, Turbonomic, and Instana, and the IBM Security and Sustainability software portfolios − all built on Red Hat OpenShift Service on AWS. The cloud-native software enables clients to deploy on AWS while flexible licensing, including SaaS and subscription, makes it easier for clients to purchase exactly how they want.

IBM is also launching 15 new IBM Consulting professional services and assets on AWS Marketplace, exclusively designed for AWS. “By expanding the availability of our software portfolio in AWS Marketplace, organizations around the world will have greater access to a streamlined way to procure many IBM AI and hybrid cloud offerings to help propel their business forward,” said Nick Otto, Head of Global Strategic Partnerships, IBM.